ir.replicel.com
RepliCel | Using Cells for HealingUsing Cells for Healing
http://ir.replicel.com/
Using Cells for Healing
http://ir.replicel.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
6.3 seconds
16x16
32x32
64x64
128x128
PAGES IN
THIS WEBSITE
1
SSL
EXTERNAL LINKS
0
SITE IP
209.205.93.22
LOAD TIME
6.329 sec
SCORE
6.2
RepliCel | Using Cells for Healing | ir.replicel.com Reviews
https://ir.replicel.com
Using Cells for Healing
RepliCel | Events
http://ir.replicel.com/events
Tel: 604-248-8730 Toll Free: 1-800-248-5255. Check to see if Replicel is speaking at an event near you. Global Chinese Financial Forum. Sep 30 2015 –. Cell Therapy Bioprocessing and Commercialization. Oct 07 2015 –. Stem Cell Meeting on the Mesa. Oct 14 2015 –. Oct 25 2015 –. Cavendish Global Impact Forum. Oct 26 2015 –. Advances in Stem Cell Research. Nov 18 2015 –. World Congress for Hair Research. Dec 09 2015 –. World Stem Cell Summit. Schulze School of Entrepreneurship, University of St Thomas.
TOTAL PAGES IN THIS WEBSITE
1
Company Information | Remark Holdings
Skip to main navigation. Investor Relations - Horizontal. Remark Holdings (NASDAQ: MARK. Mar 29, 2018. Remark Holdings Reports Fourth Quarter and Full Year 2017 Results. Mar 23, 2018. Remark Holdings Moves Up Fourth Quarter and Full Year 2017 Earnings Call to Thursday, March 29, 2018 at 8:30 am ET. Mar 16, 2018. Remark Holdings Sets Fourth Quarter and Full Year 2017 Earnings Call for Thursday, March 29, 2018 at 4:30 pm ET. Mar 09, 2018. Mar 05, 2018. Feb 12, 2018. View all press releases.
Remy - Investors Overview
Stock Quote and Chart. 160; 0.11. Data as of 08/17/15 4:00 pm ET. Minimum 20 minute delay. August 13, 2015. Remy Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Pending Acquisition Of Remy By BorgWarner. August 03, 2015. Remy International, Inc. Announces Second Quarter 2015 Results. July 30, 2015. Remy International, Inc. Announces Declaration of Dividend on Common Stock; Cancels 2nd Quarter Earnings Conference Call. There are currently no events scheduled.
Renesola - Investors - Investor Home
Stock Quote and Chart. Founded in 2005, and listed on the New York Stock Exchange in 2008, ReneSola (NYSE:SOL) is an international leading brand and technology provider of green energy products. Leveraging its global presence, expansive OEM and sales network, Renesola is well positioned to provide its highest quality green energy products and on-time services for EPC, installers, and green energy projects around the world. For more information, please visit www.renesola.com. Tel: 86-21-62809180 ext 105.
Investor Relations :: Rennova Health, Inc. (RNVA)
Rennova Health Provides Outlook for 2017. January 5, 2017. Rennova Health Provides Outlook for 2017. Jan 5, 2017. Ended Sep 30, 2016. Sign Up for Email Alerts. Be the first to receive breaking news. Jersey City, NJ 07310. 10320 N 56th Street. Tampa, FL 33617.
Renren - INVESTOR RELATIONS - Overview
Started from university campuses in 2005, we now possess a nation-wide penetration with users across all demographics, particularly college students and young white-collar professionals. Our social networking platform serves as the foundation of our business and we aim to build a mobile-centric eco-system that embodies our user needs. As a leader in mobile social networking, we are dedicated in continuing to transform ourselves into a full-fledged mobile technology Company. 160; 0.02. This calendar conta...
RepliCel | Using Cells for Healing
Tel: 604-248-8730 Toll Free: 1-800-248-5255. 4th largest cosmetics company worldwide. Ongoing tendon repair trial. Results expected in 2016. Ongoing skin rejuvenation trial. Results expected in 2016. Our stock trades on the OTCQB. And on the TSX Venture Exchange. TSXV: RP OTCQB: REPCF. Learn more about investing in RepliCel below. SIGN-UP HERE FOR FUTURE UPDATES. HERE’S WHAT INDUSTRY EXPERTS ARE SAYING:. 8220;When I can get potential blue-sky regenerative technologies like. Michael May, Centre for Commer...
Repros Therapeutics Inc. - Investor Relations
Board of Directors and Management. Events, Presentations and Webcasts. Repros in the News. Events, Presentations and Webcasts. Repros in the News. 12:34 PM ET on Jan 12, 2017. Delayed at least 20 minutes. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective. Dec 19, 2016. Dec 12, 2016. View all releases ». 2408 Timberloch Place, B-7.
Investor Relations - RGP
RGP was founded in 1996 within a Big Four accounting firm. Today, we are a publicly traded company with 3,300 professionals, annually serving over 1,700 clients around the world from 68 practice offices. Headquartered in Irvine, California, RGP has served 87 of the Fortune 100 companies. July 16, 2015. Resources Global Professionals Q415 Earnings Conference Call. Resources Global Professionals Announces Quarterly Dividend Payment Date and New Stock Buyback Authorization. To Enhance Resident Safety.
Investor Relations - RGP
RGP was founded in 1996 within a Big Four accounting firm. Today, we are a publicly traded company with 3,300 professionals, annually serving over 1,700 clients around the world from 68 practice offices. Headquartered in Irvine, California, RGP has served 87 of the Fortune 100 companies. July 16, 2015. Resources Global Professionals Q415 Earnings Conference Call. Resources Global Professionals Announces Quarterly Dividend Payment Date and New Stock Buyback Authorization. To Enhance Resident Safety.
Retrophin, Inc. - Investor Relations
Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, San Diego-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), and...
Reunert Limited Integrated Annual report 2013 | Home
2013 ANNUAL INTEGRATED REPORT. How we create value. Material issues and risks. Board and executive management. Chief executive officer’s report. Chief financial officer’s report. Social, ethics and transformation report. Company secretary’s certification. Statements of comprehensive income. Notes to the cash flow statements. Statements of changes in equity. Notes to the annual financial statements. Principal subsidiaries Annexure A. Unconsolidated subsidiary Annexure B. CHIEF EXECUTIVE OFFICER'S REPORT.
SOCIAL ENGAGEMENT